BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37150254)

  • 1. Effect of renal clearance on vancomycin area under the concentration-time curve deviations in critically ill patients.
    Ishigo T; Ibe Y; Fujii S; Kazuma S; Aigami T; Kashiwagi Y; Takada R; Takahashi S; Fukudo M; Toda T
    J Infect Chemother; 2023 Aug; 29(8):769-777. PubMed ID: 37150254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance.
    Yu YX; Lu J; Lu HD; Li L; Li JJ; Shi L; Duan LF; Zhuang ZW; Xue SD; Shen Y; Tang L
    Eur J Hosp Pharm; 2022 Mar; 29(e1):e6-e14. PubMed ID: 33414258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin.
    Hirai K; Ishii H; Shimoshikiryo T; Shimomura T; Tsuji D; Inoue K; Kadoiri T; Itoh K
    Ther Drug Monit; 2016 Dec; 38(6):706-710. PubMed ID: 27681114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients.
    Mikami R; Imai S; Hayakawa M; Sugawara M; Takekuma Y
    J Infect Chemother; 2022 Feb; 28(2):199-205. PubMed ID: 34686459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin therapeutic monitoring by measured trough concentration versus Bayesian-derived area under the curve in critically ill patients with cancer.
    AbuSara AK; Abdelrahman DH; Habash KI; Al-Shaer MH; Le J; Nazer LH
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00912. PubMed ID: 34990089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmented Renal Clearance in Pediatric Patients With Febrile Neutropenia Associated With Vancomycin Clearance.
    Hirai K; Ihara S; Kinae A; Ikegaya K; Suzuki M; Hirano K; Itoh K
    Ther Drug Monit; 2016 Jun; 38(3):393-7. PubMed ID: 27172381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Regression Model to Predict Augmented Renal Clearance in Critically Ill Obstetric Patients and Effects on Vancomycin Treatment.
    Tang L; Ding XY; Duan LF; Li L; Lu HD; Zhou F; Shi L; Lu J; Shen Y; Zhuang ZW; Sun JT; Zhou Q; Zhu CQ; Li JJ; Yu YX
    Front Pharmacol; 2021; 12():622948. PubMed ID: 34177564
    [No Abstract]   [Full Text] [Related]  

  • 8. Individualized Delivery of Vancomycin by Model-Informed Bayesian Dosing Approach to Maintain an AUC24 Target in Critically Ill Patients.
    Rao Z; Guo SM; Wei YM
    Chemotherapy; 2024; 69(1):49-55. PubMed ID: 37591210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should the trough concentration of vancomycin be abandoned in therapeutic drug monitoring? A multicentre, retrospective study of critically ill patients without any form of dialysis.
    Yu Z; Liu J; Yu H; Zhou L; Zhao Y; Zhong L; Zhu J; Liang G; Yang Y; Zheng Y; Yu L; Han G
    Int J Antimicrob Agents; 2023 Jun; 61(6):106812. PubMed ID: 37037321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulation of Vancomycin Exposure Using Trough and Peak Levels Achieves the Target Area under the Steady-State Concentration-Time Curve in ICU Patients.
    Ibe Y; Ishigo T; Fujii S; Takahashi S; Fukudo M; Sato H
    Antibiotics (Basel); 2023 Jun; 12(7):. PubMed ID: 37508208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance.
    Belabbas T; Yamada T; Egashira N; Hirota T; Suetsugu K; Mori Y; Kato K; Akashi K; Ieiri I
    J Infect Chemother; 2023 Apr; 29(4):391-400. PubMed ID: 36682608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flowchart for predicting achieving the target area under the concentration-time curve of vancomycin in critically ill Japanese patients: A multicenter retrospective study.
    Ishigo T; Fujii S; Ibe Y; Aigami T; Nakano K; Fukudo M; Yoshida H; Tanaka H; Ebihara F; Maruyama T; Hamada Y; Suzuki A; Fujihara H; Yamaguchi F; Samura M; Nagumo F; Komatsu T; Tomizawa A; Takuma A; Chiba H; Nishi Y; Enoki Y; Taguchi K; Matsumoto K
    J Infect Chemother; 2024 Apr; 30(4):329-336. PubMed ID: 37925103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A higher dose of vancomycin is needed in critically ill patients with augmented renal clearance.
    He J; Yang ZT; Qian X; Zhao B; Mao EQ; Chen EZ; Bian XL
    Transl Androl Urol; 2020 Oct; 9(5):2166-2171. PubMed ID: 33209680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients.
    Chen J; Huang X; Bu S; Chen X; Zhou J; Liu X; Guo X; Li L; Zhang J
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00885. PubMed ID: 34664790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients.
    Chuma M; Makishima M; Imai T; Tochikura N; Suzuki S; Kuwana T; Sawada N; Komatsu T; Sakaue T; Kikuchi N; Yoshida Y; Kinoshita K
    Ther Drug Monit; 2018 Feb; 40(1):109-114. PubMed ID: 29095798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Acute Kidney Injury Based on Vancomycin Target Trough Attainment Strategy: Area-Under-the-Curve-Guided Bayesian Software, Nomogram, or Trough-Guided Dosing.
    Knight JM; Iso T; Perez KK; Swan JT; Janak CE; Ikwuagwu JO; Musick WL
    Ann Pharmacother; 2024 Feb; 58(2):110-117. PubMed ID: 37144736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Vancomycin Dose Individualization Strategy by Bayesian Prediction in Patients Receiving Continuous Renal Replacement Therapy.
    Oda K; Jono H; Kamohara H; Nishi K; Tanoue N; Saito H
    Pharm Res; 2020 May; 37(6):108. PubMed ID: 32468340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin.
    Takahashi Y; Takesue Y; Takubo S; Ishihara M; Nakajima K; Tsuchida T; Ikeuchi H; Uchino M
    J Infect Chemother; 2013 Aug; 19(4):709-16. PubMed ID: 23345049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Infants, Children, and Adolescents with Augmented Renal Clearance.
    He CY; Ye PP; Liu B; Song L; van den Anker J; Zhao W
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0089721. PubMed ID: 34339268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: a multicenter retrospective study.
    Ishigo T; Matsumoto K; Yoshida H; Tanaka H; Ibe Y; Fujii S; Fukudo M; Fujihara H; Yamaguchi F; Ebihara F; Maruyama T; Hamada Y; Samura M; Nagumoi F; Komatsu T; Tomizawa A; Takuma A; Chiba H; Nishi Y; Enoki Y; Taguchi K; Suzuki A
    Microbiol Spectr; 2024 May; ():e0373923. PubMed ID: 38775483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.